PLoS One:Meta分析显示,中国心梗患者20年间他汀使用从17%增加到91.1%

2017-04-26 卢芳 中国循环杂志

北京安贞医院赵冬等对35项研究进行的Meta分析显示,1995-2015年,我国心血管二级预防药物应用明显改善,尤其是β受体阻滞剂和他汀类药物,但仍然不够充分。


北京安贞医院赵冬等对35项研究进行的Meta分析显示,1995-2015年,我国心血管二级预防药物应用明显改善,尤其是β受体阻滞剂和他汀类药物,但仍然不够充分。

研究者指出,过去20年心血管二级预防药物使用的提升,与我国医疗体系变革、医保广泛覆盖以及临床指南推广等密切相关,但仍存在一些问题,比如临床医生对指南更新认识不足,患者对疾病缺乏认知,另外医保虽比之前给力,但还需患者自费一部分,而这也有碍一部分患者长期用药。

研究显示,92%的患者应用阿司匹林,63%患者应用β受体阻滞剂,72%应用他汀类药物,49%的人用ACEI,59%的人用ARB。

此外20年来,β受体阻滞剂1995年的32%提升到78%,他汀使用从17%增加到91.1%,而硝酸酯类药物从96%降低到59.3%。

该研究共纳入35项研究2.8万名心梗或急性冠脉综合征患者,其中16项研究就入院后到出院或者出院后特定时间心血管二级预防用药进行了探讨。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1887617, encodeId=2d20188e617b5, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed May 24 01:01:00 CST 2017, time=2017-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896029, encodeId=d346189602969, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Feb 01 01:01:00 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789947, encodeId=d9291e899474b, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Apr 27 09:01:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049463, encodeId=ce252049463c7, content=<a href='/topic/show?id=5c2e5106290' target=_blank style='color:#2F92EE;'>#心梗患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51062, encryptionId=5c2e5106290, topicName=心梗患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Sat Jan 13 10:01:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193694, encodeId=431719369433, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/1A51842815047D40BFDAA8D69AA8E519/100, createdBy=fd7f2029163, createdName=绛珠草小姐, createdTime=Thu May 04 12:33:09 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191917, encodeId=536919191e2b, content=他汀药物业有其风险, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Apr 29 22:18:33 CST 2017, time=2017-04-29, status=1, ipAttribution=)]
    2017-05-24 guojianrong
  2. [GetPortalCommentsPageByObjectIdResponse(id=1887617, encodeId=2d20188e617b5, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed May 24 01:01:00 CST 2017, time=2017-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896029, encodeId=d346189602969, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Feb 01 01:01:00 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789947, encodeId=d9291e899474b, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Apr 27 09:01:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049463, encodeId=ce252049463c7, content=<a href='/topic/show?id=5c2e5106290' target=_blank style='color:#2F92EE;'>#心梗患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51062, encryptionId=5c2e5106290, topicName=心梗患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Sat Jan 13 10:01:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193694, encodeId=431719369433, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/1A51842815047D40BFDAA8D69AA8E519/100, createdBy=fd7f2029163, createdName=绛珠草小姐, createdTime=Thu May 04 12:33:09 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191917, encodeId=536919191e2b, content=他汀药物业有其风险, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Apr 29 22:18:33 CST 2017, time=2017-04-29, status=1, ipAttribution=)]
    2018-02-01 一闲
  3. [GetPortalCommentsPageByObjectIdResponse(id=1887617, encodeId=2d20188e617b5, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed May 24 01:01:00 CST 2017, time=2017-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896029, encodeId=d346189602969, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Feb 01 01:01:00 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789947, encodeId=d9291e899474b, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Apr 27 09:01:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049463, encodeId=ce252049463c7, content=<a href='/topic/show?id=5c2e5106290' target=_blank style='color:#2F92EE;'>#心梗患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51062, encryptionId=5c2e5106290, topicName=心梗患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Sat Jan 13 10:01:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193694, encodeId=431719369433, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/1A51842815047D40BFDAA8D69AA8E519/100, createdBy=fd7f2029163, createdName=绛珠草小姐, createdTime=Thu May 04 12:33:09 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191917, encodeId=536919191e2b, content=他汀药物业有其风险, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Apr 29 22:18:33 CST 2017, time=2017-04-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1887617, encodeId=2d20188e617b5, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed May 24 01:01:00 CST 2017, time=2017-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896029, encodeId=d346189602969, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Feb 01 01:01:00 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789947, encodeId=d9291e899474b, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Apr 27 09:01:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049463, encodeId=ce252049463c7, content=<a href='/topic/show?id=5c2e5106290' target=_blank style='color:#2F92EE;'>#心梗患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51062, encryptionId=5c2e5106290, topicName=心梗患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Sat Jan 13 10:01:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193694, encodeId=431719369433, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/1A51842815047D40BFDAA8D69AA8E519/100, createdBy=fd7f2029163, createdName=绛珠草小姐, createdTime=Thu May 04 12:33:09 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191917, encodeId=536919191e2b, content=他汀药物业有其风险, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Apr 29 22:18:33 CST 2017, time=2017-04-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1887617, encodeId=2d20188e617b5, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed May 24 01:01:00 CST 2017, time=2017-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896029, encodeId=d346189602969, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Feb 01 01:01:00 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789947, encodeId=d9291e899474b, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Apr 27 09:01:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049463, encodeId=ce252049463c7, content=<a href='/topic/show?id=5c2e5106290' target=_blank style='color:#2F92EE;'>#心梗患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51062, encryptionId=5c2e5106290, topicName=心梗患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Sat Jan 13 10:01:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193694, encodeId=431719369433, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/1A51842815047D40BFDAA8D69AA8E519/100, createdBy=fd7f2029163, createdName=绛珠草小姐, createdTime=Thu May 04 12:33:09 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191917, encodeId=536919191e2b, content=他汀药物业有其风险, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Apr 29 22:18:33 CST 2017, time=2017-04-29, status=1, ipAttribution=)]
    2017-05-04 绛珠草小姐

    学习了,谢谢

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1887617, encodeId=2d20188e617b5, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed May 24 01:01:00 CST 2017, time=2017-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896029, encodeId=d346189602969, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Feb 01 01:01:00 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789947, encodeId=d9291e899474b, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Apr 27 09:01:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049463, encodeId=ce252049463c7, content=<a href='/topic/show?id=5c2e5106290' target=_blank style='color:#2F92EE;'>#心梗患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51062, encryptionId=5c2e5106290, topicName=心梗患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Sat Jan 13 10:01:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193694, encodeId=431719369433, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/1A51842815047D40BFDAA8D69AA8E519/100, createdBy=fd7f2029163, createdName=绛珠草小姐, createdTime=Thu May 04 12:33:09 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191917, encodeId=536919191e2b, content=他汀药物业有其风险, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Apr 29 22:18:33 CST 2017, time=2017-04-29, status=1, ipAttribution=)]
    2017-04-29 1ddf0692m34(暂无匿称)

    他汀药物业有其风险

    0

相关资讯

Circulation:内皮CXCR7缺失损伤心梗后的血管稳态和心脏重塑

CXCR7是一种新型的血管稳态调节剂,其在内皮细胞中起作用,能够影响心功能和心梗后的心脏重塑。

PLOS ONE:周末和夜间就诊的心梗患者病情重,死亡率高

在上世纪70年代,就有学者发现了“周末效应”,所谓的周末效应就是指非工作时间入院死亡风险增加。近期中国医学科学院阜外医院高润霖院士和北京大学公共卫生学院、乔治全球健康研究院武阳丰教授等在全国99家二级医院进行的研究也证实,周末和夜间就诊的ST段抬高型心肌梗死(STEMI)患者死亡率会增加1.3%,但校正混淆因素后,没有统计学差异。研究显示,在工作时间入院的STEMI患者死亡率为7.0%,而非正式工

Chin Circul J:大于80岁高危急性心梗患者介入前预防性IABP有助于预防严重事件

近期阜外医院张沛等在《中国循环杂志》发表的一项回顾性研究显示,在80岁以上的高危急性心梗患者中,急诊冠脉介入术前预防性置入主动脉内球囊反搏(IABP)减有助于预防严重心血管事件,但对长期生存率影响不大。IABP是一种机械辅助循环的方法,通过物理作用,提高主动脉内舒张压,增加冠状动脉供血和改善心肌功能。作者分析了99例>80岁的急性心梗患者,其中24例预防性植入了IABP。在73例未植入IAB

胃部不适为何查出心梗,医生:糖尿病自行停药可致猝死风险

近日,一直以为自己是胃病的高先生在浦南医院做胃镜前被意外发现患的是冠状动脉粥样硬化、心房扑动、亚急性心肌梗死。为及时抢救患者的生命,医院心血管内科立即启动绿色通道,经紧急心脏冠脉血管介入治疗,终使他转危为安,目前已康复出院。今年已过花甲的高先生,近来感到中上腹部经常不适,一直按胃病治疗,但症状没有好转,为进一步查清病因遂到浦南医院消化内科门诊要求做一个胃镜检查。在胃镜检查前常规心电图检查后着实把心

Plos One:十年间,中国心肌梗死后使用心血管药物二次预防现状调查

目前,中国的心肌梗塞(MI)已成为患者发病和死亡的主要原因,但在过去二十年,MI事件发生后推荐的心血管药物使用情况知之甚少。近期,一项发表在杂志Plos One上的研究系统性评价了1995 - 2015年之间的心血管药物使用情况,并评估了与心血管药物趋势相关的因素。研究者们在四个数据库(Pubmed,Embase,CENTRAL和CNKI)中进行了系统的检索,以获得1995年至2015年间发表的观

Chin Circul J:NT-proBNP有助于无心衰心梗患者危险分层

对于左心室射血分数正常,且无明显舒张性心力衰竭症状的急性ST段抬高型心肌梗死(STEMI)患者而言,血浆氨基末端B 型利钠肽原(NT-proBNP)浓度有何意义?郑州大学第二附属医院赵玉兰、江冠颖等进行的研究显示,NT-proBNP在一定程度上可以反映STEMI患者的冠脉狭窄严重程度,对三支血管病变及前降支病变有一定预见作用,临床常规检测STEMI患者NT-proBNP浓度有助于其临床诊疗及危险分